Pàgina inicial > Resultats de la cerca: Multiple Sclerosis and Related Disorders
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 5 registres trobats  La cerca s'ha fet en 0.02 segons. 
1.
11 p, 1.1 MB Safety of cladribine tablets in the treatment of patients with multiple sclerosis : An integrated analysis / Cook, Stuart (Rutgers. The State University of New Jersey) ; Leist, Thomas (Jefferson University) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, Axel (Merck KGaA) ; Hicking, Christine (Merck KGaA) ; Galazka, Andrew (Merck. Zone Industrielle de L'Ouriettaz) ; Sylvester, Elke (Merck KGaA) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. [...]
2019 - 10.1016/j.msard.2018.11.021
Multiple Sclerosis and Related Disorders, Vol. 29 (april 2019) , p. 157-167  
Registre complet - Creative Commons
2.
8 p, 915.8 KB Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis / Leist, Thomas (Jefferson University) ; Cook, S. (New Jersey Medical School) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, A. (Merck KGaA) ; Damian, D. (Merck KGaA) ; Syed, S. (Merck KGaA) ; Galazka, Andrew (Merck KGaA) ; Universitat Autònoma de Barcelona
Background: Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10 mg (MAVENCLAD®; 3. 5 mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3. [...]
2020 - 10.1016/j.msard.2020.102572
Multiple Sclerosis and Related Disorders, Vol. 46 (november 2020) , p. 102572  
Registre complet - Creative Commons
3.
10 p, 683.9 KB Ozanimod in relapsing multiple sclerosis : Pooled safety results from the clinical development program / Selmaj, Krzysztof W. (University of Warmia and Mazury) ; Cohen, Jeffrey A. (Neurological Institute) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Bar-Or, Amit (University of Pennsylvania) ; Arnold, Douglas Lorne (McGill University) ; Steinman, Lawrence (Stanford University Medical Center) ; Hartung, Hans-Peter (Medical University Vienna) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Kubala Havrdova, Eva (Charles University) ; Cree, Bruce A. C (UCSF University of California San Francisco) ; Minton, Neil (Bristol Myers Squibb) ; Sheffield, James K. (Bristol Myers Squibb) ; Ding, Ning (Bristol Myers Squibb) ; Kappos, Ludwig (University of Basel) ; Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. [...]
2021 - 10.1016/j.msard.2021.102844
Multiple Sclerosis and Related Disorders, Vol. 51 (june 2021) , p. 102844  
Registre complet - Creative Commons
4.
9 p, 2.2 MB Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS / DeLuca, John (Rutgers - The State University of New Jersey, Newark) ; Schippling, Sven (University of Zurich) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Kappos, Ludwig (University of Basel) ; Cree, Bruce A. C (University of California, San Francisco) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Arnold, Douglas Lorne (McGill University, Montreal) ; Hartung, Hans Peter (Heinrich Heine University Düsseldorf) ; Sheffield, James K. (Bristol-Myers Squibb Company) ; Liu, Hongjuan (Bristol-Myers Squibb Company) ; Silva, Diego (Bristol-Myers Squibb Company) ; Cohen, Jeffrey A. (Neurological Institute, Cleveland Clinic) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Cognitive dysfunction, including slowed cognitive processing speed (CPS), is one of the most disabling symptoms of multiple sclerosis (MS). The Symbol Digit Modalities Test (SDMT) is a preferred measure of CPS for MS trials and routine screening. [...]
2021 - 10.1016/j.msard.2020.102673
Multiple Sclerosis and Related Disorders, Vol. 48 (2021) , p. 102673  
Registre complet - Creative Commons
5.
6 p, 852.9 KB Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis / Brochet, Bruno (University of Bordeaux) ; Hupperts, Raymond (Maastricht University Medical Center) ; Langdon, Dawn (Royal Holloway University of London) ; Solari, Alessandra (Fondazione IRCCS Istituto Neurologico Carlo Besta) ; Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ; Lechner-Scott, Jeannette (Newcastle University. John Hunter Hospital) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Selmaj, Krzysztof (Center for Neurology, Lodz, Poland) ; Valis, Martin (Charles University and University Hospital, Czech Republic) ; Rejdak, Konrad (Medical University of Lublin) ; Havrdova, Eva K. (Charles University, Prague, Czech Republic) ; Patti, Francesco (University of Catania) ; Alexandri, Nektaria (Merck Healthcare KGaA, Darmstadt, Germany) ; Nolting, Axel (Merck Healthcare KGaA, Darmstadt, Germany) ; Keller, Birgit (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. [...]
2022 - 10.1016/j.msard.2021.103385
Multiple Sclerosis and Related Disorders, Vol. 57 (2022) , p. 103385  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem